Nanobiotix CEO: Curadigm Spin-Out Platform Could ‘Redefine’ Drug-Body Balance
Executive Summary
Laurent Levy tells Scrip Nanobiotix’s freshly-created subsidiary Curadigm aims to improve bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.